Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2004-2-26
pubmed:abstractText
Inflammation plays an important role in the pathogenesis of several neurodegenerative diseases, including Parkinson's disease. Recent reports have indicated that andrographolide (ANDRO) has an anti-inflammatory effect by modulating macrophage and neutrophil activity. Whereas microglia, the counterpart of macrophages in the brain, are pivotal in the inflammatory process in the central nervous system, the effect of ANDRO on inflammation-mediated neurodegeneration has not been examined. In this study, we show that both pretreatment and post-treatment with ANDRO exhibited a significant protective effect against lipopolysaccharide (LPS)-induced neurotoxicity in mixed neuron-glia cultures, as determined by [(3)H]dopamine uptake and immunocytochemical analysis. In contrast, ANDRO showed no protective effect on 1-methyl-4-phenyl-pyridine (0.5 microM)-induced neurotoxicity in neuron-enriched cultures. ANDRO significantly attenuated LPS-induced microglial activation and production of reactive oxygen species, tumor necrosis factor-alpha, nitric oxide, and prostaglandin E(2). Furthermore, ANDRO dose-dependently attenuated LPS-induced inducible nitric-oxide synthase and cyclooxygenase-2 protein expression in BV-2 microglia, as determined by Western blot. These findings demonstrate that ANDRO reduces inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuron-glia cultures by inhibiting microglial activation. In addition, these results indicate that ANDRO may have clinical utility for the treatment of inflammation-related neurodegenerative disorders such as Parkinson's disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0022-3565
pubmed:author
pubmed:issnType
Print
pubmed:volume
308
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
975-83
pubmed:dateRevised
2005-11-17
pubmed:meshHeading
pubmed-meshheading:14718612-1-Methyl-4-phenylpyridinium, pubmed-meshheading:14718612-Animals, pubmed-meshheading:14718612-Cells, Cultured, pubmed-meshheading:14718612-Cyclooxygenase 2, pubmed-meshheading:14718612-Diterpenes, pubmed-meshheading:14718612-Dose-Response Relationship, Drug, pubmed-meshheading:14718612-Drug Interactions, pubmed-meshheading:14718612-Inflammation, pubmed-meshheading:14718612-Isoenzymes, pubmed-meshheading:14718612-Lipopolysaccharides, pubmed-meshheading:14718612-Male, pubmed-meshheading:14718612-Mesencephalon, pubmed-meshheading:14718612-Microglia, pubmed-meshheading:14718612-Nerve Degeneration, pubmed-meshheading:14718612-Neuroglia, pubmed-meshheading:14718612-Neurons, pubmed-meshheading:14718612-Prostaglandin-Endoperoxide Synthases, pubmed-meshheading:14718612-Rats, pubmed-meshheading:14718612-Rats, Inbred F344
pubmed:year
2004
pubmed:articleTitle
Andrographolide reduces inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuron-glia cultures by inhibiting microglial activation.
pubmed:affiliation
Neuropharmacology Section, Laboratory of Pharmacology and Chemistry, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA. wang16@niehs.nih.gov
pubmed:publicationType
Journal Article